SCHEMBL3551452

SCHEMBL3551452

CCCCc1ccc(S(=O)(=O)Nc2ccc(OCCOc3ccc(C(=O)O)cc3)cc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.63
LMNA P02545 1/20 0.63
WDR5 P61964 1/20 0.62
FFAR1 O14842 1/20 0.58
FFAR4 Q5NUL3 1/20 0.58
GFER P55789 1/20 0.56
TDP1 Q9NUW8 2/20 0.55
FABP4 P15090 1/20 0.53
TP53 P04637 2/20 0.53
MAPT P10636 2/20 0.53
LIMK2 P53671 1/20 0.53
POLB P06746 1/20 0.53
GHSR Q92847 1/20 0.53
TSHR P16473 2/20 0.52
PLA2G4B P0C869 2/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
RARB P10826 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3554413 0.95 SMN1; SMN2 (0.65) SMN1; SMN2LMNAWDR5FFAR1FFAR4
SCHEMBL3554081 0.93 LMNA (0.59) SMN1; SMN2LMNAWDR5GFERTDP1
SCHEMBL3562032 0.93 SMN1; SMN2 (0.71) SMN1; SMN2LMNAWDR5GFERTDP1
SCHEMBL3558350 0.90 FFAR1 (0.67) WDR5FFAR1FFAR4GFERLIMK2
SCHEMBL3564489 0.89 GFER (0.60) SMN1; SMN2LMNAWDR5GFERTDP1
SCHEMBL3561187 0.86 TDP1 (0.57) SMN1; SMN2LMNAWDR5TDP1TP53
SCHEMBL3553340 0.86 SMN1; SMN2 (0.56) SMN1; SMN2LMNAWDR5FFAR1FFAR4
SCHEMBL3550679 0.85 WDR5 (0.57) SMN1; SMN2LMNAWDR5TDP1TP53
SCHEMBL3554243 0.85 MEN1 (0.60) SMN1; SMN2LMNAWDR5TDP1TP53
SCHEMBL3555882 0.83 GFER (0.79) SMN1; SMN2LMNAWDR5FFAR1GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US claimed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US claimed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 SMN1; SMN2 4522/4885LMNA 2120/4885WDR5 1795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.